Who We Are

Member Companies

VP, Research and Head of Small Molecule Therapeutic Discovery (SMTD)
Amgen

Senior Vice President of Virology
Gilead Sciences

Global Public Health R&D
Johnson & Johnson

Head, Technology Licensing & Collaborations
AbbVie

Kumar Singh Saikatendu, Ph.D.

Head, Lipid Nanoparticle Platform
Takeda Pharmaceuticals

Development Unit Head
In-Market Brands and Global Health
Novartis

Head Pandemic Preparedness
Roche Pharma Research and Early Development
Roche

Chair, INTREPID Alliance
Executive Director, Global Health
IFPMA

Treasurer, INTREPID Alliance
Vice President Law
Johnson & Johnson Global Public Health

Secretary, INTREPID Alliance
Health Policy and Engagement
Johnson & Johnson

Senior Vice President of Virology
Gilead Sciences

Head Pandemic Preparedness
Roche Pharma Research and Early Development
Roche

Health Policy and Engagement
Johnson & Johnson

Partner
Ropes & Gray LLP

Elliott Levy, M.D.

Co-founder
INTREPID

Nina serves as the secretariat of the INTREPID Alliance with the responsibility of implementing the activities endorsed by the Board.

John Pottage, M.D.

Scientific Consultant

The INTREPID Alliance, Inc was registered as a Delaware non-stock corporation in April 2021, to provide a framework for start-up activities.

The Board, consisting of 7 founding member companies was elected on May 19, 2022, and terms of reference were agreed.

For more information and membership inquiries contact [email protected].